Magnesium levels and short- to medium-term cardiovascular events after percutaneous coronary intervention: a prospective cohort study
6 affiliations
- 1Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
- 2Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
- 3Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
- 4Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
- 5Clinical Pharmacy Department, Pharmacy Faculty, Isfahan University of Medical Sciences, Isfahan, Iran
- 6Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Magnesium (Mg) is an essential electrolyte that plays a critical role in cardiovascular physiology. Several studies have investigated the relationship between Mg levels and cardiovascular outcomes; however, the findings have been inconsistent. Therefore, this study aims to investigate the association between serum magnesium levels and short- to medium-term cardiovascular events in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).
Methods: This prospective cohort study was conducted at the Isfahan Cardiovascular Research Institute, Isfahan, Iran, between October 2018 and September 2023, within the framework of the Persian Cardiovascular Disease Registry. Patients were followed for short-term (1-month and 6-month) and medium-term (12-month) major adverse cardiovascular events (MACE) after PCI and were categorized into three groups according to their admission serum magnesium levels: < 1.8 mg/dL, 1.8–2.2 mg/dL, and > 2.2 mg/dL.
Results: A total of 3,640 of the 5,300 patients with a confirmed diagnosis of AMI who underwent PCI met the eligibility criteria and were included in the final analysis. The mean age of the study population was 64.70 ± 12.07 years, and 80.3% of participants were male.
At the 6-month follow-up, mortality was significantly higher among patients with serum Mg levels > 2.2 mg/dL (odds ratio [OR] = 1.45, P = 0.02). In contrast, at the 12-month follow-up, mortality was significantly higher among patients with serum Mg levels < 1.8 mg/dL (OR = 1.59, P < 0.01). The incidence of MACE was significantly higher among patients with serum Mg levels < 1.8 mg/dL at the 12-month follow-up (OR = 1.61, P < 0.01).
Conclusion: Among patients with AMI undergoing PCI, both hypomagnesemia and hypermagnesemia were associated with adverse cardiovascular outcomes during follow-up. Hypomagnesemia was associated with an increased risk of medium-term mortality and major adverse cardiovascular events, whereas hypermagnesemia was associated with increased short-term mortality. These findings suggest a potential U-shaped association between serum magnesium levels and cardiovascular outcomes in this high-risk population. As this was an observational study, these findings reflect associations rather than causal relationships. Further prospective studies are warranted to confirm these associations before any clinical application is considered.
Related
- Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention
- Association of Relative LDL-Cholesterol Reduction With Cardiovascular Outcomes After Percutaneous Coronary Intervention
- Combined Triglyceride–High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI
- Triglyceride-glucose index and risk of major adverse cardiovascular events in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention
- Effectiveness of a voice-guided tap-and-talk educational tool in enhancing cardiovascular knowledge and self-management in aged patients following percutaneous coronary intervention.
BibTeX
@article{haghighi2026magnesium,
title = {{Magnesium levels and short- to medium-term cardiovascular events after percutaneous coronary intervention: a prospective cohort study}},
author = {Razieh Bayatpour Haghighi and Ehsan Shirvani and Asieh Mansouri and Fereshte Rastegarnasab and Mehrnoush Dianatkhah and Alireza Khosravi Farsani and Saeide Bahrani and Mahnaz Jozan and Parisa Rezaei},
journal = {BMC Cardiovascular Disorders},
year = {2026},
month = aug,
doi = {10.1186/s12872-026-06401-8},
url = {https://doi.org/10.1186/s12872-026-06401-8},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Magnesium levels and short- to medium-term cardiovascular events after percutaneous coronary intervention: a prospective cohort study
AU - Razieh Bayatpour Haghighi
AU - Ehsan Shirvani
AU - Asieh Mansouri
AU - Fereshte Rastegarnasab
AU - Mehrnoush Dianatkhah
AU - Alireza Khosravi Farsani
AU - Saeide Bahrani
AU - Mahnaz Jozan
AU - Parisa Rezaei
PY - 2026
DA - 2026/08/07
JO - BMC Cardiovascular Disorders
DO - 10.1186/s12872-026-06401-8
UR - https://doi.org/10.1186/s12872-026-06401-8
AB - Background: Magnesium (Mg) is an essential electrolyte that plays a critical role in cardiovascular physiology. Several studies have investigated the relationship between Mg levels and cardiovascular outcomes; however, the findings have been inconsistent. Therefore, this study aims to investigate the association between serum magnesium levels and short- to medium-term cardiovascular events in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods: This prospective cohort study was conducted at the Isfahan Cardiovascular Research Institute, Isfahan, Iran, between October 2018 and September 2023, within the framework of the Persian Cardiovascular Disease Registry. Patients were followed for short-term (1-month and 6-month) and medium-term (12-month) major adverse cardiovascular events (MACE) after PCI and were categorized into three groups according to their admission serum magnesium levels: < 1.8 mg/dL, 1.8–2.2 mg/dL, and > 2.2 mg/dL. Results: A total of 3,640 of the 5,300 patients with a confirmed diagnosis of AMI who underwent PCI met the eligibility criteria and were included in the final analysis. The mean age of the study population was 64.70 ± 12.07 years, and 80.3% of participants were male. At the 6-month follow-up, mortality was significantly higher among patients with serum Mg levels > 2.2 mg/dL (odds ratio [OR] = 1.45, P = 0.02). In contrast, at the 12-month follow-up, mortality was significantly higher among patients with serum Mg levels < 1.8 mg/dL (OR = 1.59, P < 0.01). The incidence of MACE was significantly higher among patients with serum Mg levels < 1.8 mg/dL at the 12-month follow-up (OR = 1.61, P < 0.01). Conclusion: Among patients with AMI undergoing PCI, both hypomagnesemia and hypermagnesemia were associated with adverse cardiovascular outcomes during follow-up. Hypomagnesemia was associated with an increased risk of medium-term mortality and major adverse cardiovascular events, whereas hypermagnesemia was associated with increased short-term mortality. These findings suggest a potential U-shaped association between serum magnesium levels and cardiovascular outcomes in this high-risk population. As this was an observational study, these findings reflect associations rather than causal relationships. Further prospective studies are warranted to confirm these associations before any clinical application is considered.
SN - 1471-2261
ER -